TY - JOUR
T1 - Protective effect of carvedilol on daunorubicin-induced cardiotoxicity and nephrotoxicity in rats
AU - Arozal, Wawaimuli
AU - Watanabe, Kenichi
AU - Veeraveedu, Punniyakoti T.
AU - Ma, Meilei
AU - Thandavarayan, Rajarajan A.
AU - Sukumaran, Vijayakumar
AU - Suzuki, Kenji
AU - Kodama, Makoto
AU - Aizawa, Yoshifusa
N1 - Funding Information:
This research was supported by a Yujin Memorial Grant, Ministry of Education, Science, Sports and Culture, Japan and by a grant from the Promotion and Mutual Aid Corporation for Private Schools, Japan. We thank Sayaka Mito, Flori Ratna Sari, Hiroko Shimazaki, Kana Kawazura, and Yoshiyasu Kobayashi for their assistance in this research work. We express our sincere gratitude to Dr. Masaki Nagata (Division of Oral and Maxillofacial Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan) for carrying out the RT-PCR analysis in this study.
PY - 2010/7
Y1 - 2010/7
N2 - Daunorubicin (DNR) is one of the anthracycline anti-tumor agents widely used in the treatment of acute myeloid leukemia. However, the clinical use of DNR has been limited by its undesirable systemic toxicity, especially in the heart and kidney. This study was designed to test the effectiveness of carvedilol, a nonselective β-blocker against DNR-induced cardiotoxicity and nephrotoxicity. Rats were treated with a cumulative dose of 9. mg/kg body weight DNR (i.v.). Carvedilol was administered orally every day for 6 weeks. DNR rats showed cardiac and nephrotoxicities as evidenced by worsening cardiac and kidney functions, which were evaluated by hemodynamic and echocardiographic studies, and by measuring protein in urine, levels of urea and creatinine in serum, lipid profiles, malondialdeyde level and the total level of glutathione peroxidase activity in both heart and kidney tissues. These changes were reversed by treatment with carvedilol, which resulted in significant improvement in the cardio-renal function. Furthermore, carvedilol down-regulated matrix metalloproteinase-2 expression in the heart, increased nephrin expression in the kidney, and attenuated the increased protein expression of NADPH oxidase subunits in heart and kidney. Moreover, carvedilol reduced myocardial and renal apoptosis and improved the histopathological changes in heart and kidney induced by DNR. In conclusion, the present study demonstrated a beneficial effect of carvedilol treatment in the prevention of DNR-induced cardiotoxicity and nephrotoxicity by reversing the oxidative stress and apoptosis.
AB - Daunorubicin (DNR) is one of the anthracycline anti-tumor agents widely used in the treatment of acute myeloid leukemia. However, the clinical use of DNR has been limited by its undesirable systemic toxicity, especially in the heart and kidney. This study was designed to test the effectiveness of carvedilol, a nonselective β-blocker against DNR-induced cardiotoxicity and nephrotoxicity. Rats were treated with a cumulative dose of 9. mg/kg body weight DNR (i.v.). Carvedilol was administered orally every day for 6 weeks. DNR rats showed cardiac and nephrotoxicities as evidenced by worsening cardiac and kidney functions, which were evaluated by hemodynamic and echocardiographic studies, and by measuring protein in urine, levels of urea and creatinine in serum, lipid profiles, malondialdeyde level and the total level of glutathione peroxidase activity in both heart and kidney tissues. These changes were reversed by treatment with carvedilol, which resulted in significant improvement in the cardio-renal function. Furthermore, carvedilol down-regulated matrix metalloproteinase-2 expression in the heart, increased nephrin expression in the kidney, and attenuated the increased protein expression of NADPH oxidase subunits in heart and kidney. Moreover, carvedilol reduced myocardial and renal apoptosis and improved the histopathological changes in heart and kidney induced by DNR. In conclusion, the present study demonstrated a beneficial effect of carvedilol treatment in the prevention of DNR-induced cardiotoxicity and nephrotoxicity by reversing the oxidative stress and apoptosis.
KW - Apoptosis
KW - Carvedilol
KW - Daunorubicin
KW - Oxidative stress
UR - http://www.scopus.com/inward/record.url?scp=77954145158&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77954145158&partnerID=8YFLogxK
U2 - 10.1016/j.tox.2010.05.003
DO - 10.1016/j.tox.2010.05.003
M3 - Article
C2 - 20452391
AN - SCOPUS:77954145158
SN - 0300-483X
VL - 274
SP - 18
EP - 26
JO - Toxicology
JF - Toxicology
IS - 1-3
ER -